-
- 抗原 See all DLL4 抗体
- DLL4 (delta-Like 4 (DLL4))
-
适用
- 人
-
宿主
- 小鼠
-
克隆类型
- 单克隆
-
标记
- This DLL4 antibody is un-conjugated
-
应用范围
- Flow Cytometry (FACS)
- 特异性
- The mouse monoclonal antibody MHD4-46 recognizes the extracellular domain of DLL4 (Delta-like ligand 4), a type I transmembrane protein which plays an important role in vascular development.
- 交叉反应 (详细)
- Human
- 纯化方法
- Purified by protein-A affinity chromatography.
- 纯度
- > 95 % (by SDS-PAGE)
- 免疫原
- recombinant soluble human DLL4
- 克隆位点
- MHD4-46
- 亚型
- IgG1 kappa
- Top Product
- Discover our top product DLL4 Primary Antibody
-
-
- 应用备注
- Flow cytometry: Recommended dilution: 1-4 μg/mL
- 限制
- 仅限研究用
-
- 浓度
- 1 mg/mL
- 缓冲液
- Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
- 储存液
- Sodium azide
- 注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 储存条件
- 4 °C
- 储存方法
- Store at 2-8°C. Do not freeze.
-
-
Differential regulation of osteoclastogenesis by Notch2/Delta-like 1 and Notch1/Jagged1 axes." in: Arthritis research & therapy, Vol. 14, Issue 2, pp. R45, (2012) (PubMed).
: "Blockade of delta-like ligand 4 signaling inhibits both growth and angiogenesis of pancreatic cancer." in: Pancreas, Vol. 39, Issue 6, pp. 897-903, (2010) (PubMed).
: "Role of ephrinB2 in nonproductive angiogenesis induced by Delta-like 4 blockade." in: Blood, Vol. 113, Issue 15, pp. 3631-9, (2009) (PubMed).
: "
-
Differential regulation of osteoclastogenesis by Notch2/Delta-like 1 and Notch1/Jagged1 axes." in: Arthritis research & therapy, Vol. 14, Issue 2, pp. R45, (2012) (PubMed).
-
- 抗原
- DLL4 (delta-Like 4 (DLL4))
- 别名
- DLL4 (DLL4 产品)
- 别名
- hdelta2 antibody, Delta4 antibody, si:ch211-244p18.5 antibody, zgc:136596 antibody, delta like canonical Notch ligand 4 antibody, delta-like 4 (Drosophila) antibody, DLL4 antibody, Dll4 antibody, dll4 antibody
- 背景
- Delta like canonical Notch ligand 4,DLL4 (Delta-like 4) is one of five ligands of Notch receptors. It interacts with Notch1 and Notch4. DLL4 is up-regulated at sites of physiologic and pathologic angiogenesis, whereas its expression is low in most adult normal tissues. It is also highly expressed in human clear-cell renal carcinomas, bladder cancers, and breast cancers. Blocking the DLL4-Notch interaction seems to be a promissing therapeutic approach.,Delta like ligand 4, AOS6, canonical Notch ligand 4
- 基因ID
- 54567
- UniProt
- Q9NR61
- 途径
- Notch Signaling
-